CAI

Caris Life Sciences Inc

Sep 16 • 12:49PM ET

33.62

+0.51 1.52 %

Healthcare • Biotechnology • USA • NASD

Held by: ARKG ONEQ VTI VB VXF TMSL VBR VBK VTWO TMED

Index	-	P/E	-	EPS (ttm)	-	Insider Own	67.03%	Shs Outstand	281.09M	Perf Week	-0.96%
Market Cap	9.46B	Forward P/E	-	EPS next Y	-	Insider Trans	0.02%	Shs Float	90.68M	Perf Month	-7.88%
Enterprise Value	9.15B	PEG	-	EPS next Q	-0.17	Inst Own	35.91%	Short Float	2.13%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	127.31%	Short Ratio	1.96	Perf Half Y	-
Sales	-	P/B	20.87	EPS next Y	-	ROA	-	Short Interest	1.93M	Perf YTD	20.09%
Book/sh	1.61	P/C	13.08	EPS next 5Y	-	ROE	-	52W High	42.50 -20.88%	Perf Year	-
Cash/sh	2.57	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	25.40 32.38%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.14% 5.92%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.98	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.79	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.18	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.24	EPS Q/Q	-	SMA20	-6.97%	Beta	-	Target Price	39.44
Payout	-	Debt/Eq	0.93	Sales Q/Q	-	SMA50	3.76%	Rel Volume	0.27	Prev Close	33.12
Employees	-	LT Debt/Eq	0.91	Earnings	Aug 12 AMC	SMA200	7.34%	Avg Volume	980.84K	Price	33.62
IPO	Jun 18, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3550.94% 31.41%	Trades		Volume	141,224	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-14-25	Initiated	Wolfe Research	Outperform	$32
Jul-14-25	Initiated	TD Cowen	Buy	$32
Jul-14-25	Initiated	JP Morgan	Overweight	$31
Jul-14-25	Initiated	Guggenheim	Buy	$32
Jul-14-25	Initiated	Evercore ISI	Outperform	$33
Jul-14-25	Initiated	Citigroup	Buy	$34
Jul-14-25	Initiated	BTIG Research	Buy	$38
Jul-14-25	Initiated	BofA Securities	Buy	$31

Sep-11-25 11:17AM	Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test (Insider Monkey)
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)
Aug-15-25 08:30AM	Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek (PR Newswire)
Aug-13-25 08:30AM	New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups (PR Newswire) +5.61%
Aug-12-25 04:05PM	Caris Life Sciences Reports Second Quarter 2025 Financial Results (PR Newswire) +7.45%
08:30AM	Loading…
Aug-06-25 08:30AM	Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor (PR Newswire)
Aug-05-25 08:30AM	Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed (PR Newswire)
Jul-23-25 08:30AM	Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-22-25 08:30AM	Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis (PR Newswire) +7.07%
Jul-08-25 06:30AM	Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection (PR Newswire)
Jun-20-25 05:01AM	Caris Life Sciences indicated to open at $30, IPO priced at $21 per share (TipRanks)
Jun-18-25 02:50PM	This 'AI TechBio' company goes public as IPO demand spreads to biotech (MarketWatch)
01:37PM	The IPO Market Extends Its Comeback (Barrons.com)

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PHILLIPS T DANNY	Director	Sep 11 '25	Option Exercise	2.44	100,000	244,000	116,129	Sep 12 04:29 PM
POSTE GEORGE	Director	Aug 11 '25	Option Exercise	2.44	125,000	305,000	359,754	Aug 13 08:07 PM
Spetzler David Baxley	President	Jun 20 '25	Option Exercise	2.44	75,000	183,000	558,668	Jun 23 06:41 PM
Denton John Russel	See Remarks	Jun 20 '25	Buy	21.00	7,500	157,500	123,591	Jun 23 06:34 PM
Brille Brian J	See Remarks	Jun 20 '25	Buy	21.00	30,000	630,000	162,428	Jun 23 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAI

Caris Life Sciences Inc

Upgrade your FINVIZ experience